Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab

References

• HelmickCGLee-HanHHirschSCBairdTLBartlettCLPrevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination SurveysAm J Prev Med2014471374524746373
   PubMed Web of Science ®Google Scholar
• KimWBJeromeDYeungJDiagnosis and management of psoriasisCan Fam Physician201763427828528404701
   PubMed Web of Science ®Google Scholar
• KurdSKTroxelABCrits-ChristophPGelfandJMThe risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort studyArch Dermatol2010146889189520713823
   PubMed Web of Science ®Google Scholar
• WeissSCKimballABLiewehrDJBlauveltATurnerMLEmanuelEJQuantifying the harmful effect of psoriasis on health-related quality of lifeJ Am Acad Dermatol200247451251812271293
   PubMed Web of Science ®Google Scholar
• KimballABGladmanDGelfandJMNational Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningJ Am Acad Dermatol20085861031104218313171
   PubMed Web of Science ®Google Scholar
• OliveiraMFRochaBODuarteGVPsoriasis: classical and emerging comorbiditiesAn Bras Dermatol201590192025672294
   PubMed Web of Science ®Google Scholar
• LanganSMSeminaraNMShinDBPrevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United KingdomJ Invest Dermatol20121323 Pt 155656222113483
   PubMed Web of Science ®Google Scholar
• Canadian Psoriasis Guidelines AddendumC2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009J Cutan Med Surg201620537543127421294
   PubMed Web of Science ®Google Scholar
• SmithCHAnsteyAVBarkerJNBritish Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009Br J Dermatol20091615987101919857207
   PubMed Web of Science ®Google Scholar
• BonifatiCAmeglioFCytokines in psoriasisInt J Dermatol199938424125110321938
   PubMed Web of Science ®Google Scholar
• CarrascosaJMJacobsIPeterselDStrohalRBiosimilar drugs for psoriasis: principles, present, and near futureDermatol Ther201882173194
   PubMed Web of Science ®Google Scholar
• di CesareAdi MeglioPNestleFOThe IL-23/Th17 axis in the immunopathogenesis of psoriasisJ Invest Dermatol200912961339135019322214
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity200013571572511114383
   PubMed Web of Science ®Google Scholar
• LupardusPJGarciaKCThe structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12J Mol Biol2008382493194118680750
   PubMed Web of Science ®Google Scholar
• GordonKBDuffinKCBissonnetteRA Phase 2 trial of guselkumab versus adalimumab for plaque psoriasisN Engl J Med2015373213614426154787
   PubMed Web of Science ®Google Scholar
• LuoJWuSJLacyERStructural basis for the dual recognition of IL-12 and IL-23 by ustekinumabJ Mol Biol2010402579781220691190
   PubMed Web of Science ®Google Scholar
• LeeETrepicchioWLOestreicherJLIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisJ Exp Med2004199112513014707118
   PubMed Web of Science ®Google Scholar
• Michalak-StomaABartosińskaJKowalMJuszkiewicz-BorowiecMGerkowiczAChodorowskaGSerum levels of selected Th17 and Th22 cytokines in psoriatic patientsDis Markers201335662563124288431
   PubMed Web of Science ®Google Scholar
• BettelliEOukkaMKuchrooVKT(H)-17 cells in the circle of immunity and autoimmunityNat Immunol20078434535017375096
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSPRole of IL-17 in psoriasis and psoriatic arthritisClin Rev Allergy Immunol201344218319322362575
   PubMed Web of Science ®Google Scholar
• SofenHSmithSMathesonRTGuselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasisJ Allergy Clin Immunol201413341032104024679469
   PubMed Web of Science ®Google Scholar
• WangXWeiYXiaoHA novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like miceEur J Immunol20164661343135027019190
   PubMed Web of Science ®Google Scholar
• VignaliDAKuchrooVKIL-12 family cytokines: immunological playmakersNat Immunol201213872272822814351
   PubMed Web of Science ®Google Scholar
• CargillMSchrodiSJChangMA large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesAm J Hum Genet200780227329017236132
   PubMed Web of Science ®Google Scholar
• NairRPDuffinKCHelmsCGenome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysNat Genet200941219920419169254
   PubMed Web of Science ®Google Scholar
• ZhuangYCalderonCMarciniakSJFirst-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasisEur J Clin Pharmacol201672111303131027515978
   PubMed Web of Science ®Google Scholar
• BlauveltAPappKAGriffithsCEEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialJ Am Acad Dermatol201776340541728057360
   PubMed Web of Science ®Google Scholar
• ReichKArmstrongAWFoleyPEfficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialJ Am Acad Dermatol201776341843128057361
   PubMed Web of Science ®Google Scholar
• LangleyRGTsaiTFFlavinSEfficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trialBr J Dermatol2018178111412328635018
   PubMed Web of Science ®Google Scholar
• DeodharAGottliebABoehnckeWHEfficacy and safety results of guselkumab, an anti-Il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled studyAnn Rheum Dis201776142143
   Google Scholar
• GordonKBBlauveltAFoleyPEfficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studiesBr J Dermatol2018178113213928940259
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchMulti-discipline review/summary application numberResearch CfDEa 016761061Orig1s000
   Google Scholar
• GordonKBArmstrongAWHanCAnxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 studyJ Eur Acad Dermatol VenereolSuppl 1 Epub2018428
   Google Scholar
• AminMNoDJEgebergAWuJJDjNJjWChoosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say?Am J Clin Dermatol201819111329080066
   PubMed Web of Science ®Google Scholar
• GriffithsCEReichKLebwohlMComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet2015386999354155126072109
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• PappKAReichKPaulCA prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisBr J Dermatol2016175227328626914406
   PubMed Web of Science ®Google Scholar
• KuligPMusiolSFreibergerSNIL-12 protects from psoriasiform skin inflammationNat Commun201671346627892456
   PubMed Web of Science ®Google Scholar
• PappKAGriffithsCEGordonKLong-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upBr J Dermatol2013168484485423301632
   PubMed Web of Science ®Google Scholar
• GhilardiNKljavinNChenQLucasSGurneyALde SauvageFJCompromised humoral and delayed-type hypersensitivity responses in IL-23-deficient miceJ Immunol200417252827283314978083
   PubMed Web of Science ®Google Scholar
• HohenbergerMCardwellLAOussedikEFeldmanSRInterleukin-17 inhibition: role in psoriasis and inflammatory bowel diseaseJ Dermatolog Treat2018291131828521565
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJD’HaensGInduction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 studyLancet2017389100801699170928411872
   PubMed Web of Science ®Google Scholar
• TsaiTFHoVSongMThe safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infectionBr J Dermatol201216751145115222803615
   PubMed Web of Science ®Google Scholar
• ReichKPappKABlauveltATildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSUR-FACE 2): results from two randomised controlled, phase 3 trialsLancet20173901009127628828596043
   PubMed Web of Science ®Google Scholar
• PappKABlauveltABukhaloMRisankizumab versus ustekinumab for moderate-to-severe plaque psoriasisN Engl J Med2017376161551156028423301
   PubMed Web of Science ®Google Scholar
• GordonKBEfficacy and safety of risankizumab: results from two double-blind, placebo- and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasisPaper presented at: American Academy of Dermatology2018San Diego, CA
   Google Scholar